Works matching DE "RILPIVIRINE"

Results: 170
    1
    2
    3
    4
    5
    6
    7
    8
    9
    10

    Nanoformulations of Rilpivirine for Topical Pericoital and Systemic Coitus-Independent Administration Efficiently Prevent HIV Transmission.

    Published in:
    PLoS Pathogens, 2015, v. 11, n. 8, p. 1, doi. 10.1371/journal.ppat.1005075
    By:
    • Kovarova, Martina;
    • Council, Olivia D.;
    • Date, Abhijit A.;
    • Long, Julie M.;
    • Nochii, Tomonori;
    • Belshan, Michael;
    • Shibata, Annemarie;
    • Vincent, Heather;
    • Baker, Caroline E.;
    • Thayer, William O.;
    • Kraus, Guenter;
    • Lachaud-Durand, Sophie;
    • Williams, Peter;
    • Destache, Christopher J.;
    • Garcia, J. Victor
    Publication type:
    Article
    11
    12
    13
    14
    15
    16
    17
    18
    19
    20
    21
    22

    HIV-1 subtype B-infected MSM may have driven the spread of transmitted resistant strains in France in 2007-12: impact on susceptibility to first-line strategies.

    Published in:
    Journal of Antimicrobial Chemotherapy (JAC), 2015, v. 70, n. 7, p. 2084, doi. 10.1093/jac/dkv049
    By:
    • Frange, Pierre;
    • Assoumou, Lambert;
    • Descamps, Diane;
    • Chéret, Antoine;
    • Goujard, Cécile;
    • Tran, Laurent;
    • Gousset, Marine;
    • Avettand-Fenoël, Veronique;
    • Bocket, Laurence;
    • Fafi-Kremer, Samira;
    • Guinard, Jerome;
    • Morand-Joubert, Laurence;
    • Nicot, Florence;
    • Plantier, Jean-Christophe;
    • Rogez, Sylvie;
    • Wirden, Marc;
    • Rouzioux, Christine;
    • Meyer, Laurence;
    • Chaix, Marie-Laure
    Publication type:
    Article
    23
    24
    25
    26
    27
    28
    29
    30

    Prevalence of pre-existing resistance-associated mutations to rilpivirine, emtricitabine and tenofovir in antiretroviral-naive patients infected with B and non-B subtype HIV-1 viruses.

    Published in:
    Journal of Antimicrobial Chemotherapy (JAC), 2013, v. 68, n. 6, p. 1237, doi. 10.1093/jac/dkt003
    By:
    • Lambert-Niclot, S.;
    • Charpentier, C.;
    • Storto, A.;
    • Fofana, D. B.;
    • Soulié, C.;
    • Fourati, S.;
    • Visseaux, B.;
    • Wirden, M.;
    • Morand-Joubert, L.;
    • Masquelier, B.;
    • Flandre, P.;
    • Calvez, V.;
    • Descamps, D.;
    • Marcelin, A.-G.
    Publication type:
    Article
    31
    32
    33

    Weight Gain: A Possible Side Effect of All Antiretrovirals.

    Published in:
    Open Forum Infectious Diseases, 2017, v. 4, n. 4, p. N.PAG, doi. 10.1093/ofid/ofx239
    By:
    • Taramasso, Lucia;
    • Ricci, Elena;
    • Menzaghi, Barbara;
    • Orofino, Giancarlo;
    • Passerini, Simone;
    • Madeddu, Giordano;
    • Martinelli, Canio Vito;
    • Socio, Giuseppe Vittorio De;
    • Squillace, Nicola;
    • Rusconi, Stefano
    Publication type:
    Article
    34
    35

    Multicentre service evaluation of injectable cabotegravir and rilpivirine delivery and outcomes across 12 UK clinics (SHARE LAI‐net).

    Published in:
    HIV Medicine, 2024, v. 25, n. 10, p. 1125, doi. 10.1111/hiv.13679
    By:
    • Ring, Kyle;
    • Smuk, Melanie;
    • Shongwe, Moses;
    • Okonta, Leroy;
    • Mackie, Nicola E.;
    • Ayres, Sara;
    • Barber, Tristan J.;
    • Akodu, Jane;
    • Ferro, Filippo;
    • Chilton, Daniella;
    • Hurn, Eliot;
    • Halai, Bhavna;
    • Barchi, Will;
    • Ali, Asim;
    • Darko, Sandra;
    • White, Gemma;
    • Clarke, Emily;
    • Clark, Fiona;
    • Ali, Bazga;
    • Arumainayagam, Joseph
    Publication type:
    Article
    36
    37

    Sex differences in the effectiveness and tolerability of dolutegravir plus rilpivirine as a switch strategy in people living with HIV.

    Published in:
    HIV Medicine, 2024, v. 25, n. 6, p. 684, doi. 10.1111/hiv.13617
    By:
    • Ramos‐Ruperto, Luis;
    • Arcos‐Rueda, Maria del Mar;
    • de Miguel‐Buckley, Rosa;
    • Busca‐Arenzana, Carmen;
    • Mican, Rafael;
    • Montejano, Rocío;
    • Delgado‐Hierro, Ana;
    • Montes, María Luisa;
    • Valencia, María Eulalia;
    • Serrano, Lucía;
    • Arribas, José Ramon;
    • González, Juan;
    • Bernardino, Jose Ignacio;
    • Martín‐Carbonero, Luz
    Publication type:
    Article
    38

    Major revision version 12.0 of the European AIDS Clinical Society guidelines 2023.

    Published in:
    HIV Medicine, 2023, v. 24, n. 11, p. 1126, doi. 10.1111/hiv.13542
    By:
    • Ambrosioni, Juan;
    • Levi, Laura;
    • Alagaratnam, Jasmini;
    • Van Bremen, Kathrin;
    • Mastrangelo, Andrea;
    • Waalewijn, Hylke;
    • Molina, Jean‐Michel;
    • Guaraldi, Giovanni;
    • Winston, Alan;
    • Boesecke, Christoph;
    • Cinque, Paola;
    • Bamford, Alasdair;
    • Calmy, Alexandra;
    • Marzolini, Catia;
    • Martínez, Esteban;
    • Oprea, Cristiana;
    • Welch, Steven;
    • Koval, Anna;
    • Mendao, Luis;
    • Rockstroh, Jürgen K.
    Publication type:
    Article
    39

    Trend over time of HIV‐1 drug resistance to nonnucleoside reverse transcriptase inhibitors (NNRTIs) and their drivers: A cohort study from Antiviral Response Cohort Analysis (ARCA).

    Published in:
    HIV Medicine, 2023, v. 24, n. 11, p. 1150, doi. 10.1111/hiv.13525
    By:
    • Rancan, Ilaria;
    • Cassol, Chiara;
    • Graziani, Lucia;
    • Tilli, Marta;
    • Malcontenti, Costanza;
    • Russo, Chiara;
    • Bottanelli, Martina;
    • Bracchitta, Fiorenza;
    • Papaioannu, Rebecka;
    • Labate, Laura;
    • Mora, Sara;
    • Bezenchek, Antonia;
    • Shallvari, Adrian;
    • Di Biagio, Antonio;
    • Rossetti, Barbara
    Publication type:
    Article
    40
    41
    42
    43

    BHIVA guidelines on antiretroviral treatment for adults living with HIV‐1 2022.

    Published in:
    HIV Medicine, 2022, v. 23, p. 3, doi. 10.1111/hiv.13446
    By:
    • Waters, Laura;
    • Winston, Alan;
    • Reeves, Iain;
    • Boffito, Marta;
    • Churchill, Duncan;
    • Cromarty, Ben;
    • Dunn, David;
    • Fink, Douglas;
    • Fidler, Sarah;
    • Foster, Caroline;
    • Fox, Julie;
    • Gupta, Ravi;
    • Hilton, Andy;
    • Khoo, Saye;
    • Leen, Clifford;
    • Mackie, Nicola;
    • Naous, Nadia;
    • Ogbonmwan, Daisy;
    • Orkin, Chloe;
    • Panton, Linda
    Publication type:
    Article
    44

    Major revision version 11.0 of the European AIDS Clinical Society Guidelines 2021.

    Published in:
    HIV Medicine, 2022, v. 23, n. 8, p. 849, doi. 10.1111/hiv.13268
    By:
    • Ryom, Lene;
    • De Miguel, Rosa;
    • Cotter, Aoife Grace;
    • Podlekareva, Daria;
    • Beguelin, Charles;
    • Waalewijn, Hylke;
    • Arribas, Josè R;
    • Mallon, Patrick W. G.;
    • Marzolini, Catia;
    • Kirk, Ole;
    • Bamford, Alasdair;
    • Rauch, Andri;
    • Molina, Jean Michel;
    • Kowalska, Justyna Dominika;
    • Guaraldi, Giovanni;
    • Winston, Alan;
    • Boesecke, Christoph;
    • Cinque, Paola;
    • Welch, Steven;
    • Collins, Simon
    Publication type:
    Article
    45
    46
    47

    Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96‐week results from two randomized clinical trials.

    Published in:
    HIV Medicine, 2018, v. 19, n. 10, p. 724, doi. 10.1111/hiv.12664
    By:
    • Hagins, D;
    • Orkin, C;
    • Daar, ES;
    • Mills, A;
    • Brinson, C;
    • DeJesus, E;
    • Post, FA;
    • Morales‐Ramirez, J;
    • Thompson, M;
    • Osiyemi, O;
    • Rashbaum, B;
    • Stellbrink, H‐J;
    • Martorell, C;
    • Liu, H;
    • Liu, Y‐P;
    • Porter, D;
    • Collins, SE;
    • SenGupta, D;
    • Das, M
    Publication type:
    Article
    48
    49

    First‐line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate/emtricitabine: a durability comparison.

    Published in:
    HIV Medicine, 2018, v. 19, n. 7, p. 475, doi. 10.1111/hiv.12628
    By:
    • Taramasso, L.;
    • Di Biagio, A.;
    • Maggiolo, F.;
    • Tavelli, A.;
    • Lo Caputo, S.;
    • Bonora, S.;
    • Zaccarelli, M.;
    • Caramello, P.;
    • Costantini, A.;
    • Viscoli, C.;
    • d'Arminio Monforte, A.;
    • Cozzi‐Lepri, A.;
    • the Italian Cohort Naive Antiretrovirals (ICONA) Foundation Study Group
    Publication type:
    Article
    50